Join the Orencia group to help and get support from people like you.
Orencia News
Therapeutic Intervention Feasible for Preventing Rheumatoid Arthritis in Patients at Risk
FRIDAY, Feb. 23, 2024 – Therapeutic intervention with abatacept is feasible for patients at risk for rheumatoid arthritis, according to a study published online Feb. 13 in The Lancet. Andrew P....
Drug Used to Treat Rheumatoid Arthritis May Also Help Prevent It
THURSDAY, Feb. 15, 2024 – Philip Day loved playing soccer so much that the 35-year-old software engineer founded a website – FootballMatcher.com – to help people connect for pickup games. The fun wen...
U.S. Food and Drug Administration Approves Orencia (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)
PRINCETON, N.J.--(BUSINESS WIRE) December 15, 2021 – Bristol Myers Squibb (NYSE:BMY) today announced that Orencia (abatacept) was approved by the U.S. Food and Drug Administration (FDA) for the p...
Bristol-Myers Squibb’s Orencia (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults
PRINCETON, N.J.--(BUSINESS WIRE) July 6, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) announced today the U.S. Food and Drug Administration (FDA) has approved Orencia for the treatment of adults...
U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
PRINCETON, N.J.--(BUSINESS WIRE)--Jul 30, 2011 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) formulation of Orencia...
Further information
Related condition support groups
Rheumatoid Arthritis, Psoriatic Arthritis